N/A
Completed N=94
Tour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels
Heart Arrest · Sport Injury · Inflammatory Response · oxidative stress
Source: ClinicalTrials.gov NCT03310450 ↗
Enrolled (actual)
94
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcomePrimary: Cardiac Troponin I (cTnI) — 6.6; 10.1; 25.0 ng/dL
Summary
Prospective observational study to determine predictors that related to cardiac troponin I (cTnI) release, malondialdehyde (MDA) and high sensitivity C Reactive Protein (hs-CRP) after Tour de Borobudur (TdB) 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cardiac Troponin I (cTnI) |
6.6; 10.1; 25.0 | — |
| PRIMARY Malondialdehyde (MDA) |
206.1; 196.4; 231.2 | — |
| SECONDARY High Sensitivity C Reactive Protein (Hs-CRP) |
454; 335; 350 | — |
| SECONDARY Number of Participants With Pathological ECG Appearance |
0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- minimum sample size of 80 men, non athlete, participants of TdB
- Classified into two groups: 160kms cycling and 100kms cycling participation
- 25-55 years old
- voluntary participate in the research
- eligible in pre participatory physical examination and ECG test by doctor have no history of previous acute coronary syndrome (ACS)
Exclusion Criteria
- stop cycling before finish line due to mechanical or bicycle related errors
- (subjects who stop cycling due to any physical symptoms and health related problem included in analysis)
Data sourced from ClinicalTrials.gov (NCT03310450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.